Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Fibroblast growth factor receptor 1 signaling in adult cardiomyocytes increases contractility and results in a hypertrophic cardiomyopathy.

Cilvik SN, Wang JI, Lavine KJ, Uchida K, Castro A, Gierasch CM, Weinheimer CJ, House SL, Kovacs A, Nichols CG, Ornitz DM.

PLoS One. 2013 Dec 11;8(12):e82979. doi: 10.1371/journal.pone.0082979. eCollection 2013.

2.

Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes.

Tanaka A, Yuasa S, Mearini G, Egashira T, Seki T, Kodaira M, Kusumoto D, Kuroda Y, Okata S, Suzuki T, Inohara T, Arimura T, Makino S, Kimura K, Kimura A, Furukawa T, Carrier L, Node K, Fukuda K.

J Am Heart Assoc. 2014 Nov 11;3(6):e001263. doi: 10.1161/JAHA.114.001263.

3.

Endothelial fibroblast growth factor receptor signaling is required for vascular remodeling following cardiac ischemia-reperfusion injury.

House SL, Castro AM, Lupu TS, Weinheimer C, Smith C, Kovacs A, Ornitz DM.

Am J Physiol Heart Circ Physiol. 2016 Mar 1;310(5):H559-71. doi: 10.1152/ajpheart.00758.2015. Epub 2016 Jan 8.

4.

Dapper-1 induces myocardial remodeling through activation of canonical Wnt signaling in cardiomyocytes.

Hagenmueller M, Riffel JH, Bernhold E, Fan J, Zhang M, Ochs M, Steinbeisser H, Katus HA, Hardt SE.

Hypertension. 2013 Jun;61(6):1177-83. doi: 10.1161/HYPERTENSIONAHA.111.00391. Epub 2013 Mar 18.

5.

MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart.

Streicher JM, Ren S, Herschman H, Wang Y.

Circ Res. 2010 Apr 30;106(8):1434-43. doi: 10.1161/CIRCRESAHA.109.213199. Epub 2010 Mar 25.

6.

Wnt signaling is critical for maladaptive cardiac hypertrophy and accelerates myocardial remodeling.

Malekar P, Hagenmueller M, Anyanwu A, Buss S, Streit MR, Weiss CS, Wolf D, Riffel J, Bauer A, Katus HA, Hardt SE.

Hypertension. 2010 Apr;55(4):939-45. doi: 10.1161/HYPERTENSIONAHA.109.141127. Epub 2010 Feb 22.

7.

Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling.

Liu Q, Chen Y, Auger-Messier M, Molkentin JD.

Circ Res. 2012 Apr 13;110(8):1077-86. doi: 10.1161/CIRCRESAHA.111.260729. Epub 2012 Mar 8.

8.

Overexpression of Cardiomyocyte α1A-Adrenergic Receptors Attenuates Postinfarct Remodeling by Inducing Angiogenesis Through Heterocellular Signaling.

Zhao X, Balaji P, Pachon R, Beniamen DM, Vatner DE, Graham RM, Vatner SF.

Arterioscler Thromb Vasc Biol. 2015 Nov;35(11):2451-9. doi: 10.1161/ATVBAHA.115.305919. Epub 2015 Sep 3.

9.

Heterozygous deletion of AKT1 rescues cardiac contractility, but not hypertrophy, in a mouse model of Noonan Syndrome with Multiple Lentigines.

Roy R, Krenz M.

J Mol Cell Cardiol. 2017 Nov;112:83-90. doi: 10.1016/j.yjmcc.2017.09.003. Epub 2017 Sep 11.

PMID:
28911943
10.

Inhibition of AP-1 signaling by JDP2 overexpression protects cardiomyocytes against hypertrophy and apoptosis induction.

Hill C, Würfel A, Heger J, Meyering B, Schlüter KD, Weber M, Ferdinandy P, Aronheim A, Schulz R, Euler G.

Cardiovasc Res. 2013 Jul 1;99(1):121-8. doi: 10.1093/cvr/cvt094. Epub 2013 Apr 23.

PMID:
23612584
11.

MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress.

Huang ZP, Chen J, Seok HY, Zhang Z, Kataoka M, Hu X, Wang DZ.

Circ Res. 2013 Apr 26;112(9):1234-43. doi: 10.1161/CIRCRESAHA.112.300682. Epub 2013 Mar 22.

12.

Ginseng reverses established cardiomyocyte hypertrophy and postmyocardial infarction-induced hypertrophy and heart failure.

Moey M, Gan XT, Huang CX, Rajapurohitam V, Martínez-Abundis E, Lui EM, Karmazyn M.

Circ Heart Fail. 2012 Jul 1;5(4):504-14. doi: 10.1161/CIRCHEARTFAILURE.112.967489. Epub 2012 May 10.

13.

Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling.

Pillai VB, Sundaresan NR, Kim G, Samant S, Moreno-Vinasco L, Garcia JG, Gupta MP.

Am J Physiol Heart Circ Physiol. 2013 Feb 1;304(3):H415-26. doi: 10.1152/ajpheart.00468.2012. Epub 2012 Nov 30.

14.

Acute heart failure with cardiomyocyte atrophy induced in adult mice by ablation of cardiac myosin light chain kinase.

Massengill MT, Ashraf HM, Chowdhury RR, Chrzanowski SM, Kar J, Warren SA, Walter GA, Zeng H, Kang BH, Anderson RH, Moss RL, Kasahara H.

Cardiovasc Res. 2016 Jul 1;111(1):34-43. doi: 10.1093/cvr/cvw069. Epub 2016 Mar 29.

15.

Reversibility of adverse, calcineurin-dependent cardiac remodeling.

Berry JM, Le V, Rotter D, Battiprolu PK, Grinsfelder B, Tannous P, Burchfield JS, Czubryt M, Backs J, Olson EN, Rothermel BA, Hill JA.

Circ Res. 2011 Aug 5;109(4):407-17. doi: 10.1161/CIRCRESAHA.110.228452. Epub 2011 Jun 23.

16.

Overexpression of the serotonin 5-HT2B receptor in heart leads to abnormal mitochondrial function and cardiac hypertrophy.

Nebigil CG, Jaffré F, Messaddeq N, Hickel P, Monassier L, Launay JM, Maroteaux L.

Circulation. 2003 Jul 1;107(25):3223-9. Epub 2003 Jun 16.

17.

Raf-mediated cardiac hypertrophy in adult Drosophila.

Yu L, Daniels J, Glaser AE, Wolf MJ.

Dis Model Mech. 2013 Jul;6(4):964-76. doi: 10.1242/dmm.011361. Epub 2013 Apr 4.

18.

FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.

Touchberry CD, Green TM, Tchikrizov V, Mannix JE, Mao TF, Carney BW, Girgis M, Vincent RJ, Wetmore LA, Dawn B, Bonewald LF, Stubbs JR, Wacker MJ.

Am J Physiol Endocrinol Metab. 2013 Apr 15;304(8):E863-73. doi: 10.1152/ajpendo.00596.2012. Epub 2013 Feb 26.

19.

Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure.

Nakamura TY, Iwata Y, Arai Y, Komamura K, Wakabayashi S.

Circ Res. 2008 Oct 10;103(8):891-9. doi: 10.1161/CIRCRESAHA.108.175141. Epub 2008 Sep 5.

20.

Echocardiographic Characterization of a Murine Model of Hypertrophic Obstructive Cardiomyopathy Induced by Cardiac-specific Overexpression of Epidermal Growth Factor Receptor 2.

Sørensen LL, Bedja D, Sysa-Shah P, Liu H, Maxwell A, Yi X, Pozios I, Olsen NT, Abraham TP, Abraham R, Gabrielson K.

Comp Med. 2016;66(4):268-77.

Supplemental Content

Support Center